Next Article in Journal
The HECT E3 Ligase E6AP/UBE3A as a Therapeutic Target in Cancer and Neurological Disorders
Next Article in Special Issue
Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians
Previous Article in Journal
Role of MSC in the Tumor Microenvironment
Previous Article in Special Issue
Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
Review

Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases

1
Department of Oncology and Metabolism, Medical School, Beech Hill Road, Sheffield S10 2RX, UK
2
Department of Oncology and Metabolism, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2109; https://doi.org/10.3390/cancers12082109
Received: 3 July 2020 / Revised: 24 July 2020 / Accepted: 24 July 2020 / Published: 29 July 2020
(This article belongs to the Special Issue Targeting Bone Metastasis in Cancers)
Bone metastasis is a major cause of morbidity within solid tumours of the breast, prostate, lung and kidney. Metastasis to the skeleton is associated with a wide range of complications including bone fractures, spinal cord compression, hypercalcaemia and increased bone pain. Improved treatments for bone metastasis, such as the use of anti-bone resorptive bisphosphonate agents, within post-menopausal women have improved disease-free survival; however, these treatments are not without side effects. There is thus a need for biomarkers, which will predict the risk of developing the spread to bone within these cancers. The application of molecular profiling techniques, together with animal model systems and engineered cell-lines has enabled the identification of a series of potential bone-metastasis biomarker molecules predictive of bone metastasis risk. Some of these biomarker candidates have been validated within patient-derived samples providing a step towards clinical utility. Recent developments in multiplex biomarker quantification now enable the simultaneous measurement of up to 96 micro-RNA/protein molecules in a spatially defined manner with single-cell resolution, thus enabling the characterisation of the key molecules active at the sites of pre-metastatic niche formation as well as tumour-stroma signalling. These technologies have considerable potential to inform biomarker discovery. Additionally, a potential future extension of these discoveries could also be the identification of novel drug targets within cancer spread to bone. This chapter summarises recent findings in biomarker discovery within the key bone metastatic cancers (breast, prostate, lung and renal cell carcinoma). Tissue-based and circulating blood-based biomarkers are discussed from the fields of genomics, epigenetic regulation (micro-RNAs) and protein/cell-signalling together with a discussion of the potential future development of these markers towards clinical development. View Full-Text
Keywords: bone metastatic cancers; biomarkers; personalised medicine; micro-RNA; proteins; bone microenvironment bone metastatic cancers; biomarkers; personalised medicine; micro-RNA; proteins; bone microenvironment
Show Figures

Figure 1

MDPI and ACS Style

Wood, S.L.; Brown, J.E. Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers 2020, 12, 2109. https://doi.org/10.3390/cancers12082109

AMA Style

Wood SL, Brown JE. Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases. Cancers. 2020; 12(8):2109. https://doi.org/10.3390/cancers12082109

Chicago/Turabian Style

Wood, Steven L., and Janet E. Brown. 2020. "Personal Medicine and Bone Metastases: Biomarkers, Micro-RNAs and Bone Metastases" Cancers 12, no. 8: 2109. https://doi.org/10.3390/cancers12082109

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop